GLP-1 Shortage Tracker: FDA Status by Drug and Strength
Liraglutide is on the FDA shortage list now. The rest are resolved.
- In shortage now
- 1
- Molecules tracked
- 4
- Source
- FDA drug shortage list
| Molecule | Brands | FDA status | What happened | Compounding allowed |
|---|---|---|---|---|
| Tirzepatide | Mounjaro, Zepbound | Resolved | Shortage resolved. FDA confirmed it on December 19, 2024. | 503A until February 18, 2025; 503B until March 19, 2025 |
| Semaglutide | Ozempic, Wegovy, Rybelsus | Resolved | Injection shortage resolved on February 21, 2025. Old Rybelsus tablets are being discontinued. | 503A until April 22, 2025; 503B until May 22, 2025 |
| Liraglutide | Victoza, Saxenda, generic liraglutide | In shortage | Still listed as a current shortage. Victoza pens have limited availability, and generic versions are available. In January 2027, Saxenda is being discontinued. | Not listed |
| Dulaglutide | Trulicity | Not listed | It is not included in current FDA shortage data; Lilly says all Trulicity doses are available. | Not listed |
Download the shortage status as CSV
Sources: FDA 1 2 3, api.fda.gov, ashp.org.
Half-life and weight loss overview
Half-life in days means how long the body needs to clear half of a dose. Section 12.3 of each FDA label provides this information.
Body weight percentage. Each result should be compared with the placebo on its own page because the trials, doses, and lengths differ.
Grouped by strength and pack
| Molecule | Pack or strength | Status | Availability |
|---|---|---|---|
| Semaglutide | Rybelsus tablet 3 mg, 7 mg, 14 mg | To Be Discontinued | Replaced by Ozempic (semaglutide) tablets |
| Liraglutide | Victoza 6 mg/mL pen (2-pack and 3-pack) | Current | Limited Availability |
| Liraglutide | Victoza back order | Current | Back order |
| Liraglutide | Saxenda 6 mg/mL pen (5-pack) | To Be Discontinued | Available until January 2027 |
| Liraglutide | Generic liraglutide (Meitheal, Teva) | Current | Available |
Sources: api.fda.gov, ashp.org.
Compounded GLP-1s: what it means
- Neither Tirzepatide nor semaglutide currently appears on the 503B bulks list or FDA's drug shortage list.
- On April 30, 2026, FDA set out a proposal that would keep semaglutide, tirzepatide, and liraglutide off the 503B bulks list.
- The FDA received 990 adverse event reports for compounded semaglutide (as of 2026-05-31)
- The FDA received more than 730 adverse event reports for compounded tirzepatide (as of 2026-05-31)
Source: FDA.